Hostname: page-component-76d6cb85b7-lrvh5 Total loading time: 0 Render date: 2026-07-15T09:21:12.002Z Has data issue: false hasContentIssue false
  • English
  • Français

Niacin (nicotinic acid) in non-physiological doses causes hyperhomocysteineaemia in Sprague–Dawley rats

Published online by Cambridge University Press:  09 March 2007

Tapan K. Basu ,
Neelam Makhani  and
Gary Sedgwick
Tapan K. Basu*
Affiliation:
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, T6G 2P5 Canada
Neelam Makhani
Affiliation:
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, T6G 2P5 Canada
Gary Sedgwick
Affiliation:
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, T6G 2P5 Canada
*
*Corresponding author: Dr Tapan K. Basu, fax +1 780 492 9130, email tbasu@afns.ualberta.ca
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Niacin (nicotinic acid) in its non-physiological dose level is known to be an effective lipid-lowering agent; its potential risk as a therapeutic agent, however, has not been critically considered. Since niacin is excreted predominantly as methylated pyridones, requiring methionine as a methyl donor, the present study was undertaken to examine whether metabolism of the amino acid is altered in the presence of large doses of niacin. Male Sprague–Dawley rats were given a nutritionally adequate, semi-synthetic diet containing niacin at a level of either 400 or 1000 mg/kg diet (compared to 30 mg/kg in the control diet) for up to 3 months. Supplementation with niacin (1000 mg/kg diet) for 3 months resulted in a significant increase in plasma and urinary total homocysteine levels; this increase was further accentuated in the presence of a high methionine diet. The hyperhomocysteineaemia was accompanied by a significant decrease in plasma concentrations of vitamins B6 and B12, which are cofactors for the metabolism of homocysteine. The homocysteine-raising action of niacin, in particular, has an important toxicological implication, as hyperhomocysteineaemia is considered to be an independent risk factor for arterial occlusive disease. The niacin-associated change in homocysteine status may be an important limiting factor in the use of this vitamin as a lipid-lowering agent.

Keywords

NiacinHomocysteineMethionineCysteineB-vitamins

Information

Type
Research Article
Information
British Journal of Nutrition , Volume 87 , Issue 2 , February 2002 , pp. 115 - 119
Copyright
Copyright © The Nutrition Society 2002

References

Basu, TK & Mann, S (1997) Vitamin B6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. Journal of Nutrition 127, 117–121.CrossRefGoogle ScholarPubMed
Boushey, CJ, Beresford, SAA, Omenn, GS & Motulsky, AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. Journal of the American Medical Association 274, 997–1092.Google Scholar
Capuzzi, DM, Guyton, JR, Morgan, JM, Goldberg, AC, Kreisberg, RA, Brusco, OA & Brody, J (1998) Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. American Journal of Cardiology 82, 74U–81U.CrossRefGoogle ScholarPubMed
D'Angelo, A, Mazzola, G, Crippa, L, Fermo, I & D'Angeloo, SV (1997) Hyperhomocysteinemia and venous thromboembolic disease. Haematologica 82, 211–219.Google ScholarPubMed
DenHeijer, M, Koster, T & Blom, HJ (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. New England Journal of Medicine 334, 759–762.CrossRefGoogle Scholar
Finkelstein, JD (1998) The metabolism of homocysteine: pathways and regulation. European Journal of Pediatrics 157, S40–S44.CrossRefGoogle Scholar
Finkelstein, JD (2000) Homocysteine: A history in progress. Nutrition Reviews 58, 193–204.CrossRefGoogle ScholarPubMed
Finkelstein, JD & Martin, JJ (1986) Methionine metabolism in mammals. Journal of Biological Chemistry 261, 1582–1587.CrossRefGoogle ScholarPubMed
Goldberg, AC (1998 a) Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. American Journal of Cardiology 82, 35U–38U.CrossRefGoogle ScholarPubMed
Guyton, JR (1998 b) Effect of niacin on cardiovascular disease. American Journal of Cardiology 82, 18U–23U.CrossRefGoogle ScholarPubMed
Jacobsen, DW (1998) Homocysteine and vitamins in cardiovascular disease. Clinical Chemistry 44, 1833–1843.CrossRefGoogle ScholarPubMed
Keenan, JM, Fontaine, PL, Wenz, JB, Huang, ZQ & Ripsin, CM (1991) A randomized controlled trial of wax-matrix sustained release niacin in hypercholesterolemia. Archives of Internal Medicine 151, 1424–1432.CrossRefGoogle ScholarPubMed
Knopp, RH (1998) Clinical profiles of plain versus sustained-release niacin and the physiologic rationale for nighttime dosing. Americal Journal of Cardiology 82, 35U–38U.Google ScholarPubMed
McKenney, JM, Proctor, JD, Harris, S & Chinchili, VM (1994) A comparison of the efficacy and toxic effects of sustained- versus immediate-release niacin in hypercholesterolemic patients. Journal of American Medical Association 271, 672–676.CrossRefGoogle Scholar
Mansoor, MA, Svardal, AM & Ueland, PM (1992) Determination of the in vivo redox status of cysteine, cysteineylglycine, homocysteine and glutathione in human plasma. Analytical Biochemistry 200, 218–229.CrossRefGoogle ScholarPubMed
Refsum, H, Ueland, PM, Nygard, O & Vollset, SE (1998) Homocysteine and cardiovascular disease. Annual Review of Medicine 49, 31–62.CrossRefGoogle ScholarPubMed
Sedgwick, GW, Fenton, TW & Thompson, JR (1991) Effect of protein precipitating agents on the recovery of plasma free amino acids. Canadian Journal of Animal Science 71, 953–957.CrossRefGoogle Scholar
Shibata, K & Matsuo, H (1989) Correlation between niacin equivalent intake and urinary excretion of its metabolites: N 1 methylnicotinamide N 1 -methy 1-2-pyridone-5-carboxamide, and N 1-methy l-4-pyridone-3-carboxamide, in humans consuming a self-selected food. American Journal of Clinical Nutrition 50, 114–119.CrossRefGoogle Scholar
Shin-Buckring, Y, Rasshofer, R & Endres, W (1981) A new enzymatic method for pyridoxal-5′-phosphate determination. Journal of Inherited Metabolic Disease 4, 123–124.CrossRefGoogle Scholar
Steel, RGD & Torrie, JH (1953) Principles and procedures of statistics: A Biometrical Approach, pp. 67–119. New York, NY: McGraw-Hill.Google Scholar
Stipanuk, MH (1986) Metabolism of sulfur-containing amino acids. Annual Review of Nutrition 6, 179–209.CrossRefGoogle ScholarPubMed
Verhoef, P, Henneckens, C, Allen, R, Stabler, S, Willet, W & Stampfer, M (1997) Plasma total homocysteine and risk of angina pectoris with subsequent coronary bypass artery surgery. American Journal of Cardiology 79, 799–801.CrossRefGoogle Scholar
Welch, G & Loscalzo, J (1998) Homocysteine and atherosclerosis. New England Journal of Medicine 338, 1042–1049.CrossRefGoogle Scholar